sv

Alla / NYSE / NUVB.US

Nuvation Bio

Nuvation Bio

Investera provisionsfritt

Köp och sälj delar av aktier för så lite som 1 €

1 d
1 v
1 m
3 m
1 å
MAX

Info och statistik

Dagens utbud
1 d−100,00 %
3 m−100,00 %
1 v−100,00 %
6 m−100,00 %
1 m−100,00 %
1 å−100,00 %
SYMBOL
NUVB
MARKNAD
NYSE
ISIN
US67080N1019

Datum

Stängnings

Förändring

Förändring (%)

Öppnings

Högt

Lågt

5,980,284,68 %5,706,045,65
5,760,162,78 %5,605,905,58
5,560,081,44 %5,485,605,30
5,330,193,56 %5,145,375,08
5,12−0,02−0,39 %5,145,285,02
5,140,101,95 %5,045,194,85
4,920,061,22 %4,865,224,85
4,760,224,62 %4,544,834,44
4,58−0,34−7,42 %4,924,984,49
4,93−0,18−3,65 %5,115,674,54
4,80−0,09−1,87 %4,894,984,74
4,82−0,28−5,81 %5,105,174,69
5,170,468,9 %4,715,434,71
4,72−0,12−2,54 %4,844,884,57
4,90−0,08−1,63 %4,985,004,66
4,960,234,64 %4,735,034,70
4,780,071,46 %4,714,814,59
4,75−0,02−0,42 %4,774,824,61
4,740,030,63 %4,715,054,65
4,69−0,10−2,13 %4,794,814,60
4,72−0,12−2,54 %4,844,924,61
4,790,438,98 %4,364,864,34
4,510,255,54 %4,264,604,21
4,240,081,89 %4,164,304,05
4,21−0,14−3,33 %4,354,424,16
4,32−0,34−7,87 %4,664,694,23
4,72−0,20−4,24 %4,924,924,64
4,780,000 %4,784,894,67
4,840,081,65 %4,764,904,63
4,760,030,63 %4,734,894,71
4,79−0,06−1,25 %4,854,924,67
4,81−0,21−4,37 %5,025,134,69
5,040,071,39 %4,975,184,78
4,830,5110,56 %4,324,874,10
4,41−0,10−2,27 %4,514,864,37
4,490,081,78 %4,414,564,35
4,45−0,01−0,22 %4,464,514,30
4,34−0,15−3,46 %4,494,514,19
4,56−0,04−0,88 %4,604,644,44
4,56−0,28−6,14 %4,845,174,51
4,89−0,13−2,66 %5,025,154,74
5,04−0,07−1,39 %5,115,254,96
5,12−0,14−2,73 %5,265,305,05
5,11−0,03−0,59 %5,145,275,00
5,120,081,56 %5,045,204,86
5,080,203,94 %4,885,124,82
4,81−0,04−0,83 %4,854,894,59
4,82−0,06−1,24 %4,884,934,74
4,850,122,47 %4,734,944,69
4,700,142,98 %4,564,774,51
4,60−0,04−0,87 %4,644,674,36
4,630,194,1 %4,444,684,42
4,53−0,32−7,06 %4,854,854,43
4,510,153,33 %4,364,554,22
4,45−0,07−1,57 %4,524,664,41
4,410,010,23 %4,404,624,39
4,510,132,88 %4,384,614,36
4,290,173,96 %4,124,324,11
4,05−0,19−4,69 %4,244,334,02
4,25−0,19−4,47 %4,444,604,18
4,420,153,39 %4,274,494,23
4,38−0,06−1,37 %4,444,504,33
4,280,040,93 %4,244,384,19
4,35−0,08−1,84 %4,434,504,17
4,22−0,04−0,95 %4,264,394,12
4,260,102,35 %4,164,344,09
4,28−0,08−1,87 %4,364,394,22
4,40−0,14−3,18 %4,544,584,31
4,50−0,08−1,78 %4,584,654,41
4,44−0,01−0,23 %4,454,594,28
4,37−0,10−2,29 %4,474,474,28
4,59−0,04−0,87 %4,634,754,50
4,69−0,07−1,49 %4,764,844,63
4,730,265,5 %4,474,814,41
4,590,051,09 %4,544,754,40
4,57−0,05−1,09 %4,624,744,44
4,740,255,27 %4,494,814,23
4,36−0,37−8,49 %4,734,844,13
5,840,183,08 %5,665,895,50
5,910,264,4 %5,655,955,61
5,800,223,79 %5,585,845,46
5,56−0,17−3,06 %5,735,825,49
5,640,061,06 %5,585,785,33
5,460,071,28 %5,395,645,29
5,440,020,37 %5,425,615,32
5,48−0,30−5,47 %5,785,795,39
5,77−0,02−0,35 %5,796,025,67
5,880,244,08 %5,645,975,64
5,77−0,10−1,73 %5,876,075,68
5,79−0,01−0,17 %5,805,915,48
5,720,172,97 %5,555,775,46
5,71−0,01−0,18 %5,725,895,59
5,64−0,20−3,55 %5,845,945,28
5,70−0,19−3,33 %5,896,155,65
5,62−0,22−3,91 %5,846,165,57
5,860,030,51 %5,836,035,48
5,900,264,41 %5,645,965,53
5,630,417,28 %5,225,655,18
5,24−0,05−0,95 %5,295,405,09
5,340,000 %5,345,415,20
5,30−0,28−5,28 %5,585,665,24
5,610,050,89 %5,565,755,52
5,50−0,03−0,55 %5,535,625,42
5,59−0,37−6,62 %5,966,015,52
5,91−0,28−4,74 %6,196,275,83
6,150,050,81 %6,106,275,87
6,010,376,16 %5,646,115,58
5,85−0,33−5,64 %6,186,275,79
6,14−0,30−4,89 %6,446,496,03
6,31−0,28−4,44 %6,596,646,18
6,55−0,02−0,31 %6,576,596,04
6,46−1,19−18,42 %7,657,676,29
8,04−0,38−4,73 %8,428,557,99
8,45−0,25−2,96 %8,708,878,33
8,840,333,73 %8,519,118,51
8,49−0,16−1,88 %8,658,718,37
8,590,080,93 %8,518,648,01
8,58−0,39−4,55 %8,979,068,26
8,960,091 %8,879,158,86
8,94−0,13−1,45 %9,079,088,82
9,06−0,21−2,32 %9,279,458,85
9,40−0,12−1,28 %9,529,579,23
9,520,060,63 %9,469,589,18
9,340,000 %9,349,549,05
9,54−0,01−0,1 %9,559,789,38
9,440,454,77 %8,999,548,98
8,990,343,78 %8,659,098,55
8,52−0,09−1,06 %8,618,888,38
8,660,222,54 %8,448,838,11
8,510,141,65 %8,378,578,22
8,430,293,44 %8,148,577,98
8,270,212,54 %8,068,537,95
7,84−0,02−0,26 %7,868,077,78
8,00−0,48−6 %8,488,837,97
8,58−0,16−1,86 %8,748,988,41
8,550,202,34 %8,358,728,12
8,310,060,72 %8,258,598,08
8,370,657,77 %7,728,407,53
7,47−0,44−5,89 %7,917,957,42
7,88−0,01−0,13 %7,898,057,73
8,03−0,05−0,62 %8,088,167,89
8,010,182,25 %7,838,267,79
7,880,455,71 %7,437,957,31
7,410,334,45 %7,087,516,98
6,990,030,43 %6,967,176,50
7,01−0,17−2,43 %7,187,526,82
7,152,1730,35 %4,987,374,94
4,800,153,12 %4,654,974,56
4,67−0,16−3,43 %4,834,944,59
4,860,306,17 %4,565,364,53
4,69−0,20−4,26 %4,894,974,63
4,93−0,07−1,42 %5,005,184,80
4,980,418,23 %4,575,044,50
4,64−0,22−4,74 %4,864,894,53
4,73−0,11−2,33 %4,845,034,44
5,020,122,39 %4,905,204,77
4,920,265,28 %4,665,024,49
4,83−0,32−6,63 %5,155,153,89
5,17−0,22−4,26 %5,395,395,08
5,220,132,49 %5,095,355,04
5,150,020,39 %5,135,425,08
5,26−0,14−2,66 %5,405,565,08
5,370,305,59 %5,075,475,00
5,040,112,18 %4,935,144,79
4,850,438,87 %4,424,894,40
4,390,081,82 %4,314,424,06
4,15−0,02−0,48 %4,174,343,89
4,210,5312,59 %3,684,243,64
3,700,246,49 %3,463,733,43
3,41−0,09−2,64 %3,503,643,33
3,63−0,19−5,23 %3,823,863,56
3,770,184,77 %3,593,823,49
3,55−0,12−3,38 %3,673,673,48
3,68−0,12−3,26 %3,803,803,57
3,74−0,02−0,53 %3,763,823,52
3,750,020,53 %3,733,833,62
3,720,102,69 %3,623,823,59
3,66−0,11−3,01 %3,773,793,49
3,770,030,8 %3,743,903,62
3,71−0,04−1,08 %3,753,853,64
3,71−0,01−0,27 %3,723,773,57
3,70−0,01−0,27 %3,713,853,50
3,700,3710 %3,333,973,28
3,220,020,62 %3,203,333,12
3,200,195,94 %3,013,282,97
3,01−0,15−4,98 %3,163,232,97
3,240,020,62 %3,223,423,15
3,22−0,01−0,31 %3,233,323,14
3,270,030,92 %3,243,323,12
3,220,000 %3,223,323,12
3,17−0,17−5,36 %3,343,483,12
3,260,010,31 %3,253,423,19
3,270,144,28 %3,133,433,06
3,15−0,05−1,59 %3,203,233,05
3,14−0,19−6,05 %3,333,373,06
3,350,092,69 %3,263,473,21
3,32−0,02−0,6 %3,343,433,24
3,35−0,19−5,67 %3,543,543,23
3,49−0,31−8,88 %3,803,853,17
3,900,4210,77 %3,484,103,46
3,420,236,73 %3,193,513,12
3,150,165,08 %2,993,212,97
2,95−0,01−0,34 %2,963,052,89
2,970,041,35 %2,933,012,85
2,92−0,04−1,37 %2,963,102,87
2,95−0,06−2,03 %3,013,072,87
2,980,113,69 %2,873,052,84
2,88−0,01−0,35 %2,893,012,80
2,900,155,17 %2,753,012,73
2,740,020,73 %2,722,872,66
2,710,082,95 %2,632,752,54
2,69−0,24−8,92 %2,932,952,64
2,900,113,79 %2,792,942,69
2,750,000 %2,752,872,69
2,760,134,71 %2,632,792,56
2,610,2810,73 %2,332,732,31
2,320,062,59 %2,262,352,18
2,24−0,09−4,02 %2,332,352,15
2,30−0,11−4,78 %2,412,562,26
2,340,010,43 %2,332,522,18
2,350,020,85 %2,332,392,22
2,370,083,38 %2,292,422,24
2,310,062,6 %2,252,342,19
2,23−0,04−1,79 %2,272,352,19
2,360,041,69 %2,322,482,31
2,41−0,09−3,73 %2,502,582,32
2,46−0,05−2,03 %2,512,602,39
2,550,031,18 %2,522,782,49
2,500,000 %2,502,602,43
2,510,000 %2,512,632,44
2,560,166,25 %2,402,602,33
2,350,010,43 %2,342,432,29
2,35−0,06−2,55 %2,412,512,29
2,300,031,3 %2,272,422,21
2,240,020,89 %2,222,352,17
2,230,062,69 %2,172,322,12
2,13−0,03−1,41 %2,162,252,05
2,14−0,10−4,67 %2,242,262,03
2,20−0,10−4,55 %2,302,312,14
2,31−0,05−2,16 %2,362,422,22
2,370,208,44 %2,172,452,12
2,05−0,06−2,93 %2,112,172,00
2,080,031,44 %2,052,182,00
2,090,062,87 %2,032,141,98
2,050,094,39 %1,962,091,87
1,94−0,02−1,03 %1,962,001,84
1,95−0,06−3,08 %2,012,121,92
1,93−0,05−2,59 %1,982,051,90
1,970,126,09 %1,852,001,78
1,88−0,14−7,45 %2,022,051,83
2,05−0,02−0,98 %2,072,162,00
2,030,062,96 %1,972,051,89
1,970,031,52 %1,942,031,81
1,790,126,7 %1,671,841,55
1,71−0,15−8,77 %1,861,871,68
1,860,158,06 %1,711,911,55
1,73−0,06−3,47 %1,791,831,66
1,81−0,37−20,44 %2,182,251,77
2,20−0,34−15,45 %2,542,741,95
2,530,000 %2,532,672,45
2,51−0,03−1,2 %2,542,552,40
2,48−0,08−3,23 %2,562,632,43
2,48−0,01−0,4 %2,492,562,36
2,45−0,02−0,82 %2,472,552,40
2,450,093,67 %2,362,482,25
2,340,166,84 %2,182,402,13
2,12−0,12−5,66 %2,242,282,08
2,26−0,01−0,44 %2,272,302,15
2,20−0,02−0,91 %2,222,372,10
2,24−0,14−6,25 %2,382,442,20
2,300,093,91 %2,212,362,14
2,250,198,44 %2,062,291,97
2,03−0,16−7,88 %2,192,231,98
2,17−0,12−5,53 %2,292,332,07
2,300,083,48 %2,222,412,19
2,260,041,77 %2,222,312,17
2,240,073,13 %2,172,282,09
2,17−0,04−1,84 %2,212,252,07
2,19−0,01−0,46 %2,202,252,08
2,15−0,10−4,65 %2,252,272,07
2,09−0,02−0,96 %2,112,172,00
2,10−0,12−5,71 %2,222,321,95
2,04−0,07−3,43 %2,112,161,97
2,09−0,35−16,75 %2,442,442,05
2,38−0,09−3,78 %2,472,542,35
2,460,124,88 %2,342,562,29
2,270,031,32 %2,242,322,17
2,250,156,67 %2,102,302,10
2,180,020,92 %2,162,222,07
2,160,041,85 %2,122,232,10
2,130,041,88 %2,092,162,05
2,130,062,82 %2,072,172,03
2,08−0,08−3,85 %2,162,252,02
2,060,073,4 %1,992,131,95
1,980,052,53 %1,932,071,87
1,970,042,03 %1,932,021,86
1,88−0,19−10,11 %2,072,081,79
2,020,031,49 %1,992,071,92
2,020,020,99 %2,002,101,89
1,990,199,55 %1,802,061,70
1,750,000 %1,751,801,60
1,790,137,26 %1,661,861,58
1,66−0,25−15,06 %1,911,921,60
1,800,2413,33 %1,561,851,51
1,66−0,01−0,6 %1,671,711,54
1,66−0,03−1,81 %1,691,771,61
1,790,042,23 %1,751,881,69
1,75−0,02−1,14 %1,771,811,64
1,76−0,01−0,57 %1,771,801,66
1,82−0,05−2,75 %1,871,901,77
1,870,010,53 %1,861,931,82
1,88−0,06−3,19 %1,941,991,82
1,94−0,04−2,06 %1,982,071,88
1,960,000 %1,962,001,82
1,89−0,05−2,65 %1,941,961,83
1,96−0,01−0,51 %1,972,011,87
1,98−0,03−1,52 %2,012,011,87
1,96−0,13−6,63 %2,092,091,90
2,09−0,10−4,78 %2,192,192,01
2,14−0,12−5,61 %2,262,332,09
2,21−0,02−0,9 %2,232,322,06
2,24−0,10−4,46 %2,342,442,16
2,290,4318,78 %1,862,371,79
1,880,031,6 %1,851,951,76
2,020,115,45 %1,912,091,77
1,890,010,53 %1,881,921,77
1,870,158,02 %1,721,921,68
1,820,021,1 %1,801,861,67
1,82−0,27−14,84 %2,092,221,77
1,970,010,51 %1,962,041,86
1,97−0,02−1,02 %1,992,091,93
1,98−0,09−4,55 %2,072,131,94
2,05−0,03−1,46 %2,082,111,95
2,08−0,14−6,73 %2,222,242,05
2,21−0,09−4,07 %2,302,352,17
2,27−0,05−2,2 %2,322,332,22
2,300,010,43 %2,292,372,26
2,32−0,01−0,43 %2,332,392,23
2,27−0,07−3,08 %2,342,382,23
2,290,041,75 %2,252,352,22
2,280,114,82 %2,172,342,14
2,23−0,01−0,45 %2,242,342,19
2,28−0,12−5,26 %2,402,432,24
2,38−0,05−2,1 %2,432,442,26
2,410,000 %2,412,472,35
2,45−0,02−0,82 %2,472,502,32
2,410,062,49 %2,352,452,22
2,270,020,88 %2,252,382,20
2,31−0,07−3,03 %2,382,512,26
2,40−0,04−1,67 %2,442,562,35
2,420,000 %2,422,532,38
2,45−0,04−1,63 %2,492,512,36
2,50−0,06−2,4 %2,562,602,38
2,52−0,27−10,71 %2,792,842,47
2,770,051,81 %2,722,842,59
2,650,114,15 %2,542,742,53
2,580,041,55 %2,542,692,48
2,51−0,09−3,59 %2,602,632,44
2,54−0,03−1,18 %2,572,632,45
2,60−0,06−2,31 %2,662,782,47
2,59−0,01−0,39 %2,602,642,47
2,67−0,01−0,37 %2,682,732,43
2,78−0,12−4,32 %2,903,012,70
3,01−0,28−9,3 %3,293,292,89
3,250,319,54 %2,943,472,94
Visa mer

Data som visas är för perioden 07 jan. 2025 - 23 juni 2026 .
Ändrings-, öppnings-, stängnings-, höga och låga värden baseras på den dagliga köpkursen för NUVB.

Liknande diskussioner

MikePetrov

för 4 dagar sedan

Two Months In: Strong Growth From Nuvation Bio and Caris Life Sciences

For the past two months, I've been invested in Nuvation Bio and Caris Life Sciences. Their stock prices have performed very well.

Moc

för 5 månader sedan

NUVB reported preliminary net product revenue of $24.7 million for IBTROZI since launch

Nuvation Bio Inc. (NUVB) reported preliminary net product revenue of $24.7 million for IBTROZI since its launch in June 2025, with fourth quarter revenue reaching $15.7 million. The company said 432 patients started treatment on IBTROZI for advanced ROS1-positive non-small cell lung cancer since the drug’s launch, with 216 new patients beginning treatment in the fourth quarter. The treatment adoption rate is approximately six times greater than prior ROS1 tyrosine kinase inhibitor launches based on IQVIA data, according to the company. Nuvation Bio received a $25 million milestone payment from Nippon Kayaku in the fourth quarter following establishment of a reimbursement price in Japan. The company reported preliminary cash, cash equivalents and marketable securities of approximately $529.2 million as of December 31, 2025. On January 11, 2026, the company entered an exclusive license and collaboration agreement with Eisai Co., Ltd. to develop, register and commercialize taletrectinib for ROS1-positive non-small cell lung cancer in Europe, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand, Singapore, the Philippines, Indonesia, Thailand, Malaysia, Vietnam and India. IBTROZI received FDA approval on June 11, 2025, for treating adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer following Priority Review and Breakthrough Therapy designations. The company plans to continue enrollment of its phase 3 study evaluating safusidenib in high-grade and high-risk IDH1-mutant gliomas and pursue business development opportunities to expand its pipeline. The preliminary financial results are subject to adjustment pending completion of the company’s financial closing procedures. Nuvation Bio expects to issue full financial results for the fourth quarter and full year 2025 in March 2026.

Moc

för 7 månader sedan

Good news

$NUVB announced the publication of positive Phase 2 study results for safusidenib in treating grade 2 IDH1-mutant glioma patients. The findings were published in the journal Neuro-Oncology on November 8. The study evaluated 27 patients with IDH1-mutant grade 2 gliomas who had received no prior anticancer therapy except for resection or biopsy. The trial met its primary endpoint with an objective response rate of 44.4%. At 24 months, 87.9% of patients remained progression-free. Median progression-free survival had not been reached as of the March 10, 2023 data cutoff, with a median follow-up time of 28 months. The median duration of response could not be estimated because no progression events had occurred. Adverse events were described as mostly mild to moderate. Grade 3 or greater treatment-related adverse events occurred in five patients (18.5%). Three patients discontinued treatment due to adverse events, two of which investigators considered related to safusidenib. The company noted that a Good Clinical Practice noncompliance issue regarding adverse event collection was identified during the study. Safety data was subsequently re-investigated and re-collected according to study protocol. Safusidenib is an oral, brain-penetrant inhibitor of mutant IDH1. Nuvation Bio is progressing the ongoing G203 study in high-grade IDH1-mutant gliomas, with a protocol amendment planned to finalize the study as a global Phase 3 trial to support potential regulatory approvals. The company stated that as of September 15, 2025, 12 patients remained on treatment with safusidenib. Gliomas are the most common type of brain cancer in adults, with nearly 2,400 people diagnosed with IDH1-mutant gliomas annually in the United States.

BailyW

för 7 månader sedan

Up?

Has this got anymore juice? Holding nicely. What do people think?

Denna sida kan innehålla användargenererat innehåll som Trading 212 inte ansvarar för. Skaffa alltid information på egen hand. Trading 212 är en execution only-tjänst, vilket innebär att Trading 212 inte erbjuder några investeringsråd eller någon portföljförvaltning.

Relaterade instrument

Bank of New York Mellon

+19,95 (+15,64 %)

First Western Financial

+4,21 (+15,89 %)

Grab

−0,40 (−10,47 %)

Hercules Capital

+0,29 (+1,94 %)

Burford Capital

−0,17 (−3,90 %)

Credit Acceptance

+130,09 (+27,97 %)

Jasper Therapeutics

−0,3300 (−41,13 %)

NewtekOne

+1,54 (+12,53 %)

Better Home & Finance Holding

−6,10 (−18,63 %)

Coincheck Group

+0,33 (+19,41 %)

Invesco Mortgage Capital

−0,61 (−7,24 %)

GCM Grosvenor

+2,37 (+24,38 %)

Provisionsfri investering för alla

Köp och sälj Nuvation Bio Inc +0,23 $ (3,99 %) och över 13 000 globala aktier och ETF:er

Andra avgifter kan tillkomma. Se våra Villkor och avgifter.

Se våra villkor och avgifter här

phone

Köp aktier direkt

Välj ditt favoritföretag

Välj hur mycket du vill investera

Få dina aktier på några sekunder

Att bygga förmögenhet är en vana.
Automatisera det med ett pie.

Investera i färdiga pies eller skapa ditt eget genom att välja bland tusentals aktier och ETF

Läs mer

Läs mer

Titta på videon

Förvärva även de dyraste aktierna som Google, Amazon och Apple.

Titta på videon

Flag fr

Euronext
Paris

Flag us

NYSE,
NASDAQ

Flag de

Xetra,
Gettex

Flag nl

Euronext Amsterdam

Flag es

Bolsa
de Madrid

Flag at

Wiener
Börse

Flag uk

London Stock Exchange

Flag pt

Euronext Lissabon

Flag fr

Euronext
Paris

Flag us

NYSE,
NASDAQ

Flag de

Xetra,
Gettex

Flag nl

Euronext Amsterdam

Flag es

Bolsa
de Madrid

Flag at

Wiener
Börse

Flag uk

London Stock Exchange

Flag pt

Euronext Lissabon

Se alla handelsinstrument

Support dygnet runt

29 sekunder genomsnittlig svarstid

Börja bygga rikedom nu

Bli en av över 5 miljoner användare

Hämta appen

Öppna konto

Skaffa mobilappen

qr-code

Alla presenterade statistik är global. Antalet kunder representerar finansierade Konto.

Utmärkt

Betyg 4,6 / 5 baserat på 95 591 recensioner av

Trustpilot

Betyg 4,6 / 5 baserat på 95 591 recensioner av

Trustpilot

Inbjuden

Love the Trading 212 App it’s great fun…

Love the Trading 212 App it’s great fun to use and it’s really intuitive in helping you to monitor your investments as they grow!

Richard Knights

4 dagar sedan

Inbjuden

Safe,simple and easy

Great website, easy to use. Regular updates. Sit back and do nothing. Couldn’t be simpler. Very happy.

Nigel

4 dagar sedan

Inbjuden

Great app and easy to use

The Trading 212 app is easy to use and I like the fact you can see your investment grow on a daily basis.

Hazel

4 dagar sedan

Inbjuden

Very easy account making/saving…

It’s been so easy to create accounts and start investing/saving would recommend to anyone

BLaw

4 dagar sedan

Inbjuden

Best app

This investment app is very easy to use and has a user-friendly interface. I feel confident knowing my money is secure, and the investment process is simple and straightforward. The customer support is also responsive and helpful whenever needed. Highly recommended for anyone looking for a reliable investment platform!

Teesside Customer

4 dagar sedan

Inbjuden

Easy and stress free

Investing is made very easy with Trading 212.

HMN

4 dagar sedan

Inbjuden

Easy to use

Easy to set up easy to use deposit and take out

Mr S Axford

4 dagar sedan

Inbjuden

The best trading app out there

The best trading app out there. No question

Paul

4 dagar sedan

Inbjuden

Easy to use

Easy to use. I love it

Mark White

4 dagar sedan

Inbjuden

Low fees ETFs + on of the best interest…

Low fees ETFs + on of the best interest rate on cash attached

Pavel Voronkin

4 dagar sedan

Inbjuden

Easy to use

Easy to use, recommend if you’re interested in investing

Ben

4 dagar sedan

Inbjuden

Very helpful and professional and my…

Very helpful and professional and my query was dealt with quickly and efficiently.

Mrs Mazzotta

4 dagar sedan

Inbjuden

All good!

Till now, almost a year after start using it, the experience has been going very well. No issues with any of the activities I needed to perform, friendly user interface and enough tools. I'm also glad that looks like the team ears the community. Keep up the good work.

Hugo Valadas

4 dagar sedan

Inbjuden

A great platform to invest

A great platform to invest. The app is easy to navigate. Easy to transfer money.

Simon C

4 dagar sedan

Used stocks and shares ISA as well as…

Used stocks and shares ISA as well as Cash ISA. Like the stocks interface, info about financials of the companies. It does not work very reliably on niche stocks or ETFs, but I would be surprised if it did. Also it tracks the ISA limits, ISAs are flexible. So can take money in and out all the time. Withdrawals are very quick. They tell it may take few businesses days, but usually goes through in a few minutes (if not seconds). Cash ISA interest was high, not it is not really, but I suppose it is a price for ability to withdraw anytime. It would be nice if I could buy government bonds there as stocks and shares ISA product.

Ruslan Lytvynov

5 dagar sedan

Inbjuden

Great experience.

Orders execution is really smooth, level of transparency is amazing when it comes to clear track of transactions and pies is very helpful. If they just can enable higher freedom when it comes to communication between members in one community/pie, it will be amazing.

ahmed elsayes

5 dagar sedan

Inbjuden

Great app

Great app. Very easy to use. No complications atall

customer

5 dagar sedan

Inbjuden

Great even for beginners

Really easy to use and track investments. Fees are clear and fair. The ability to communicate with other investors for support is a good feature, especially for beginners. I'm a newbie to stocks and shares, this app has been perfect to learn with as well as actual investments.

Paul Carr

5 dagar sedan

Inbjuden

T212 - The SIPP’er heros.

The Trading 212 team pretty much does all the heavy lifting when setting up a SIPP, you do need to supply the obvious details, and will most likely need to respond to your previous pension provider to confirm your sure with the transfer. But as far as pension pot transfers go, T212 is fantastic! They looked into potential loss of protected terms and brought this up quickly for me to make a decision. The response time from the team is really quick and professional- I cant recommend them enough. I also really like the SIPP interface on the app, its really easy to understand and is seamless with your other investment accounts. 10/10.

Thomas Warren

5 dagar sedan

Inbjuden

Great site makes investing very easy…

Great site makes investing very easy and exciting, still a little confused on some things but getting there, thanks

Mr Cursons

5 dagar sedan

Visa några av våra positiva kundrecensioner

Våra utmärkelser

Vanliga frågor och svar

Vad är aktiekursen för Nuvation Bio (NUVB)?

Det aktuella priset för Nuvation Bio (NUVB) är 5,99 $.

Vad är 52‑veckorshögsta för NUVB?

Högsta nivån på 52 veckor för NUVB är 9,78 $.

Vad är 52-veckorslägstanoteringen för NUVB?

Den lägsta nivån på 52 veckor för NUVB är 1,78 $.

Vad är den veckovisa prestandan för NUVB?

Under den senaste veckan har priset på NUVB ändrats med 16,99 %.

Hur ser den månatliga prestationen för NUVB ut?

Under den senaste månaden har priset på NUVB ändrats med 26,91 %.

Vad är 3-månadersprestandan för NUVB?

Under de senaste tre månaderna har priset på NUVB ändrats med 41,94 %.

Hur har 6‑månadersavkastningen för NUVB varit?

Under de senaste sex månaderna har priset på NUVB förändrats med −37,21 %.

Vad är den årliga prestandan för NUVB?

Under det senaste året har priset på NUVB förändrats med 204,06 %.